218 related articles for article (PubMed ID: 34000917)
1. Trastuzumab-emtansine induced pleural and pericardial effusions.
Lombardi J; Lory P; Martin N; Mayeur D; Combret S; Grandvuillemin A; Boulay C; Schmitt A
J Oncol Pharm Pract; 2021 Dec; 27(8):2041-2044. PubMed ID: 34000917
[TBL] [Abstract][Full Text] [Related]
2. Ado-trastuzumab emtansine associated spider telangiectasia.
Gursoy P; Acar A; Acikalin T
J Oncol Pharm Pract; 2022 Jun; 28(4):986-988. PubMed ID: 35040682
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
4. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
5. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
Lepelley M; Allouchery M; Long J; Boucherle D; Ranchoup Y; Le Marc'Hadour F; Villier C; Sturm N
Ann Hepatol; 2018 Oct; 17(6):1067-1071. PubMed ID: 30600283
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
Barginear MF; John V; Budman DR
Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
[TBL] [Abstract][Full Text] [Related]
9. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
Muzaffar M; Jia J; Liles D; Naveed M; Kumari A
Am J Ther; 2016; 23(2):e572-4. PubMed ID: 25756468
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
11. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.
Yan H; Endo Y; Shen Y; Rotstein D; Dokmanovic M; Mohan N; Mukhopadhyay P; Gao B; Pacher P; Wu WJ
Mol Cancer Ther; 2016 Mar; 15(3):480-90. PubMed ID: 26712117
[TBL] [Abstract][Full Text] [Related]
12. [Clinical research progress of T-DM1 in breast cancer].
Li LX; Ma F
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):92-97. PubMed ID: 33472319
[TBL] [Abstract][Full Text] [Related]
13. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine: mechanisms of action and drug resistance.
Barok M; Joensuu H; Isola J
Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
[TBL] [Abstract][Full Text] [Related]
15. Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients.
Lee A; Larck C; Moore DC
J Oncol Pharm Pract; 2022 Jan; 28(1):49-54. PubMed ID: 33356991
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.
Dhillon S
Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374
[TBL] [Abstract][Full Text] [Related]
17. Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab.
LaMorte D; Desmond D; Ellis J; Lipkowitz S
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479891
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
Salvestrini V; Kim K; Caini S; Alkner S; Ekholm M; Skyttä T; Becherini C; Coles CE; Kaidar-Person O; Offersen B; de Azambuja E; Visani L; Cortes J; Harbeck N; Rugo HS; Isacke CM; Marangoni E; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
Radiother Oncol; 2023 Sep; 186():109805. PubMed ID: 37437610
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
